Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727, Venetoclax, and Gilteritinib for FLT3-Mutated AML or High-Risk MDS
NCT05010122Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2021
- Primary completion
- Jan 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gilteritinib, venetoclax and inqovi in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days and Overall Response Rate. Started Jul 2021; status: recruiting.
02
Drugs
gilteritinibvenetoclaxinqovi
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05010122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05010122.